{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:15:42Z","timestamp":1784754942323,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40265-025-02197-7","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T10:39:45Z","timestamp":1750675185000},"page":"1059-1065","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tiratricol: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2197_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2024.1444919","volume":"12","author":"AJ Bauer","year":"2024","unstructured":"Bauer AJ, Auble B, Clark AL, et al. Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review. Front Pediatr. 2024;12:1\u201311.","journal-title":"Front Pediatr"},{"issue":"6","key":"2197_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ETJ-24-0286","volume":"13","author":"B Markova","year":"2024","unstructured":"Markova B, Mayerl S, Heuer H. Toward a treatment for thyroid hormone transporter MCT8 deficiency - achievements and challenges. Eur Thyroid J. 2024;13(6):1\u20139.","journal-title":"Eur Thyroid J"},{"key":"2197_CR3","unstructured":"European Medicines Agency. Emcitate 350 microgram dispersible tablets: summary of product characteristics. 2025. https:\/\/ec.europa.eu\/. Accessed 7 Mar 2025"},{"key":"2197_CR4","unstructured":"Egetis Therapeutics. European Commission approves Egetis' Emcitate(Rm) (tiratricol) as the first and only treatment for patients with MCT8 deficiency [media release]. 13 Feb 2025. http:\/\/www.egetis.com."},{"key":"2197_CR5","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Emcitate. 2024. https:\/\/www.ema.europa.eu\/. Accessed 7 Mar 2025"},{"issue":"Suppl. 3","key":"2197_CR6","first-page":"77","volume":"97","author":"C Sonesson","year":"2024","unstructured":"Sonesson C, Carroll K, Singh N, et al. The first robust bioavailability\/bioequivalence (BA\/BE) study of thyromimetic tiratricol, a treatment in development for MCT8 deficiency. Horm Res Paediatr. 2024;97(Suppl. 3):77.","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2197_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ajcp\/aqab124","volume":"157","author":"SL Chan","year":"2022","unstructured":"Chan SL, Refetoff S, Babic N, et al. Triiodothyroacetic acid cross-reacts with measurement of triiodothyronine (T3) on various immunoassay platforms. Am J Clin Pathol. 2022;157(2):156\u20138.","journal-title":"Am J Clin Pathol"},{"issue":"Suppl. 4","key":"2197_CR8","first-page":"124","volume":"96","author":"M Freund","year":"2023","unstructured":"Freund M, Chatterjee K, van Geest F, et al. Effects of tiratricol treatment withdrawal in MCT8 deficiency: ReTRIACt Trial [abstract no. T2]. Horm Res Paediatr. 2023;96(Suppl. 4):124\u20135.","journal-title":"Horm Res Paediatr"},{"key":"2197_CR9","unstructured":"Egetis Therapeutics. Egetis has decided to explore RTH-beta as the next indication for tiratricol (Emcitate)(R) [media release]. http:\/\/www.egetis.com. 4 Dec 2024"},{"key":"2197_CR10","unstructured":"PledPharma. PledPharma completes the acquisition of Rare Thyroid Therapeutics [media release].  3 Nov 2020. http:\/\/www.pledpharma.com."},{"key":"2197_CR11","unstructured":"PledPharma. PledPharma changes its name to Egetis Therapeutics with focus on late stage orphan drug development [media release]. 17 Dec 2020. http:\/\/www.pledpharma.com."},{"key":"2197_CR12","unstructured":"Egetis Therapeutics, Fujimoto Pharmaceutical Corporation. Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan [media release]. 10 Nov 2023. http:\/\/www.egetis.com."},{"key":"2197_CR13","unstructured":"Egetis Therapeutics. Egetis submits a patent application to the United States Patent and Trademark Office for \"Processes of Preparation\" of tiratricol [media release]. 19 Sept 2024. http:\/\/www.egetis.com."},{"issue":"1\u20132","key":"2197_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0303-7207(00)00266-5","volume":"165","author":"N Messier","year":"2000","unstructured":"Messier N, Langlois MF. Triac regulation of transcription is T(3) receptor isoform- and response element-specific. Mol Cell Endocrinol. 2000;165(1\u20132):57\u201366.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2197_CR15","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1210\/en.2012-1628","volume":"154","author":"S Horn","year":"2013","unstructured":"Horn S, Kersseboom S, Mayerl S, et al. Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter Mct8. Endocrinology. 2013;154(2):968\u201379.","journal-title":"Endocrinology"},{"issue":"12","key":"2197_CR16","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1210\/me.2014-1135","volume":"28","author":"S Kersseboom","year":"2014","unstructured":"Kersseboom S, Horn S, Visser WE, et al. In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency. Mol Endocrinol. 2014;28(12):1961\u201370.","journal-title":"Mol Endocrinol"},{"issue":"7","key":"2197_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.174645","volume":"9","author":"F Salas-Lucia","year":"2024","unstructured":"Salas-Lucia F, Escamilla S, Bianco AC, et al. Impaired T3 uptake and action in MCT8-deficient cerebral organoids underlie Allan-Herndon-Dudley syndrome. JCI Insight. 2024;9(7):1\u201316.","journal-title":"JCI Insight."},{"issue":"4","key":"2197_CR18","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.3390\/ijms24043452","volume":"24","author":"J Chen","year":"2023","unstructured":"Chen J, Salveridou E, Liebmann L, et al. Triac treatment prevents neurodevelopmental and locomotor impairments in thyroid hormone transporter Mct8\/Oatp1c1 deficient mice. Int J Mol Sci. 2023;24(4):3452.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"2197_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms232415547","volume":"23","author":"JR Reinwald","year":"2022","unstructured":"Reinwald JR, Weber-Fahr W, Cosa-Linan A, et al. TRIAC treatment improves impaired brain network function and white matter loss in thyroid hormone transporter Mct8\/Oatp1c1 deficient mice. Int J Mol Sci. 2022;23(24):1\u201319.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2197_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/thy.2022.0562","volume":"33","author":"C Grijota-Mart\u00ednez","year":"2023","unstructured":"Grijota-Mart\u00ednez C, Montero-Pedrazuela A, Hidalgo-\u00c1lvarez J, et al. Intracerebroventricular high doses of 3,3\u2032,5-triiodothyroacetic acid at juvenile stages improve peripheral hyperthyroidism and mediate thyromimetic effects in limited brain regions in a mouse model of monocarboxylate transporter 8 deficiency. Thyroid. 2023;33(4):501\u201310.","journal-title":"Thyroid"},{"issue":"9","key":"2197_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S2213-8587(19)30155-X","volume":"7","author":"S Groeneweg","year":"2019","unstructured":"Groeneweg S, Peeters RP, Moran C, et al. Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(9):695\u2013706.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2197_CR22","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.1210\/clinem\/dgab750","volume":"107","author":"FS van Geest","year":"2022","unstructured":"van Geest FS, Groeneweg S, van den Akker ELT, et al. Long-term efficacy of T3 analogue Triac in children and adults with MCT8 deficiency: a real-life retrospective cohort study. J Clin Endocrinol Metab. 2022;107(3):e1136\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"2197_CR23","unstructured":"Egetis Therapeutics. Egetis announces topline results of the phase 2 Triac Trial II with Emcitate(Rm) (tiratricol) for MCT8 deficiency [media release]. 19 June 2024. http:\/\/www.egetis.com."},{"key":"2197_CR24","unstructured":"European Medicines Agency. CHMP public assessment report (Emcitate). 2025. https:\/\/www.ema.europa.eu\/. Accessed 31 Mar 2025"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02197-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02197-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02197-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T21:40:51Z","timestamp":1757194851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02197-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02197-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"4 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code availability"}}]}}